Eikonoklastes Therapeutics
Dr. Vishal Agrawal joined Eikonoklastes in 2022 as the Vice President of CMC and Process Development. Prior to joining Eikonoklastes, Vishal worked at a number of successful private and publicly-traded biotech companies with increasing responsibility in both antibody and gene therapy manufacturing. Dr. Agrawal completed his Bachelors and Masters in Biochemical Engineering at The Indian Institutes of Technology Delhi and his PhD in Cell Biology at Max-Delbruck Centre.
This person is not in any offices
Eikonoklastes Therapeutics
1 followers
Eikonoklastes is advancing a new generation of tissue factor (TF) immunotherapies – therapeutics designed to target the cell surface receptor now known to be prevalent on key components of the tumor microenvironment.